Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Lowers the risk of undergoing coronary revascularization procedures and slow the…. Sold as Lescol, Lescol Xl. Every FDA application for this active ingredient: 2 branded and 6 generic.
As of Nov 15, 2026, FDA lists 8 applications for Fluvastatin Sodium (sold as Lescol, Lescol Xl), first approved Dec 31, 1993, with 12 new uses approved and 0 published complete response letters.
First approved: Dec 31, 1993
Applications: 8
New uses approved: 12
Complete response letters: 0
Medicare spending, 2025: $6.6M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Fluvastatin Sodium
Part D
$3.2M
-3%
6,544
Fluvastatin ER
Part D
$2.9M
-18%
4,062
Lescol XL
Part D
$417K
-21%
119
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
FLUVASTATIN ER 80 MG TABLET: $2.87 per unitGeneric · +6% in a year
FLUVASTATIN SODIUM 20 MG CAP: $2.64 per unitGeneric · -17% in a year
FLUVASTATIN SODIUM 40 MG CAP: $3.00 per unitGeneric · +2% in a year
LESCOL XL 80 MG TABLET: $13.06 per unitBrand · 0% in a year
FDA Drug Safety Communications
One communication since 2020 that name this drug; see all communications
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA